-
1 week ago | 
venousnews.com | Eva Malpass
A recent research article has detailed an artificial intelligence (AI) model that enables physicians to predict which patients with superficial venous insufficiency have a higher risk of developing deep vein thrombosis (DVT) following endovenous thermal ablation (EVTA).
-
1 week ago | 
vascularnews.com | Eva Malpass
Penumbra has announced the completion of enrolment in the STORM-PE clinical trial. The pivotal, prospective, multicentre randomised controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash plus anticoagulation versus anticoagulation alone for the treatment of acute intermediate-high risk pulmonary embolism (PE).
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
“We’re living in a new world order” when it comes to “no-option” chronic limb-threatening ischaemia (CLTI) patients, says Anahita Dua (Massachusetts General Hospital, Boston, USA). In recent years, into this arena has stepped transcatheter arterialisation of the deep veins (TADV), raising hopes of reducing amputation rates amid a rise in diabetes and other disease affecting microvascular dissemination.
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
HistoSonics has announced that it has completed enrolment in a pivotal trial to evaluate its histotripsy platform in treating kidney tumours. The US company’s prospective, multicentre, single-arm pivotal #HOPE4KIDNEY trial is designed to evaluate the effectiveness and safety of the Edison system for the destruction of kidney tissue by treating primary solid renal tumours. A total of 67 patients have been enrolled with a single, non-metastatic solid kidney mass ≤3cm.
-
2 weeks ago | 
interventionalnews.com | Eva Malpass
Penumbra has announced the US Food and Drug Administration (FDA) clearance and launch of the Ruby XL system. The Ruby XL system is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes—especially in large vessel and high-flow embolization, details a recent company press release.
-
3 weeks ago | 
vascularspecialistonline.com | Eva Malpass
An evaluation of trends in the utilization of carotid artery stenting (CAS) versus carotid endarterectomy (CEA) has found there to be “no major change” to tip the balance following the 2023 US Centers for Medicare and Medicaid Services (CMS) expansion of CAS coverage to include standard-risk patients with symptomatic ≥50% and asymptomatic ≥70% carotid artery stenosis. Courtenay M.
-
3 weeks ago | 
vascularspecialistonline.com | Eva Malpass
Concerns were raised yesterday’s Plenary Session 2 over the recent decline in Medicare reimbursement at a national level. Querying current figures, speakers revealed discrepancies which highlight the importance of accurate reporting to ensure sustainable provision for the future of vascular care. Opening the session, Kirthi S.
-
3 weeks ago | 
interventionalnews.com | Eva Malpass
TriSalus Life Sciences has announced the launch of the TriNav FLX infusion system. The TriNav FLX infusion system retains the same trusted pressure-enabled drug delivery (PEDD) benefits as existing products but introduces an important advancement in design, states a recent company press release. The new system features twice the length of flexible material at the distal end, allowing for easier navigation through more tortuous vessels.
-
3 weeks ago | 
interventionalnews.com | Eva Malpass
Portal vein embolization (PVE) is a crucial preoperative procedure designed to induce hypertrophy of the future liver remnant (FLR) in patients requiring major hepatectomy. Among the embolic agents available, n-butyl cyanoacrylate (nBCA) combined with lipiodol has emerged as one of the most effective options for PVE, shares José Hugo Luz (Brazilian National Cancer Institute, Rio de Janeiro, Brazil), promoting a high yield of liver hypertrophy and requires only a minimal volume of contrast media.
-
3 weeks ago | 
interventionalnews.com | Eva Malpass
With a focus on magnetic resonance imaging (MRI)-guided procedures and cancer signalling pathways which promote cancer resistance to ablation, David Woodrum (Mayo Clinic, Rochester, USA) discusses how advancements in MRI have solidified its place in the diagnosis and treatment of prostate cancer. Focal prostate ablation continues to challenge the standard paradigm for prostate cancer treatment.
